Clinical trial Recruiting at 1 site Interventional Ages 18 and up

PENG block: continuous infusion versus programmed intermittent bolus for hip fracture pain

Official title: A Double Blind Randomised Controlled Trial Comparing Continuous Infusion vs. Programmed Intermittent Bolus Via a Pericapsular Nerve Group (PENG) Catheter for Post Operative Fractured Neck of Femur Analgesia

Run by University College Cork · NCT07046052 · Data updated 2026-11-12

This will see if giving levobupivacaine through a PENG block as a continuous infusion or as timed intermittent boluses provides better pain relief for adults after neck of femur (hip) fracture surgery.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment150 (estimated)
SponsorUniversity College Cork
Academic / other
Locations1 site (Cork, Cork)
StatusRecruiting
StartedMarch 28, 2024
Main results expectedJanuary 7, 2026
Study endsJanuary 7, 2026
Registry record updatedJuly 1, 2025
Trial IDNCT07046052 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) having hemiarthroplasty for a fractured neck of femur who can give written consent, speak English, and have no contraindications to peripheral nerve blocks are the ideal candidates.

Probably not a fit

Patients with contraindications to peripheral nerve block (local infection, allergy to local anaesthetic, coagulopathy), those under 50 kg, pregnant women, vulnerable adults under guardianship, or people with chronic pain and long-term opioid use may not gain benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Pericapsular Nerve Group (PENG) block is a regional analgesia technique used to control pain after neck of femur fracture. In this interventional protocol patients undergoing hemiarthroplasty receive a PENG block with an indwelling catheter and are assigned to either continuous infusion or programmed intermittent bolus delivery of levobupivacaine. Analgesic effectiveness, opioid consumption, delirium incidence, and adverse events are recorded in the postoperative period to compare the two dosing strategies. The trial is conducted at Cork University Hospital and enrolls adult patients able to provide written consent.

Why it matters

Potential benefit: If successful, one dosing strategy could provide better or longer-lasting pain relief after hip fracture surgery and reduce opioid use and related complications.

How similar studies have gone: PENG blocks have been shown to provide effective analgesia after hip fracture, but direct comparisons between continuous infusion and programmed intermittent bolus dosing have not been clearly established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* English-speaking
* over the age of 18 years
* hemiarthroplasty for fractured neck of femur
* able to provide written consent.

Exclusion Criteria:

* under 50kg body weight.
* unable to provide consent due to incapacity
* pregnant women
* vulnerable adults under state guardianship
* Patients with pre-existing chronic pain disorders or with a history of long-term opioid use
* those with contraindications to a peripheral nerve block such as local site infection, allergy to local anaesthetic or those who are coagulopathic

Where it's running

  • Cork University Hospital
    Cork, Cork, Ireland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.